FOXO4-DRI vs Thymalin
Research Verdict
Neither compound has a universal evidence advantage. Research distinction: Senescence-focused aging research using the Baar 2017 paradigm vs. Immune aging (immunosenescence) research where thymic restoration is the target, accepting Khavinson.
Quick Answers
Which is better, FOXO4-DRI or Thymalin?
Neither compound has a universal evidence advantage. Research distinction: Senescence-focused aging research using the Baar 2017 paradigm vs. Immune aging (immunosenescence) research where thymic restoration is the target, accepting Khavinson.
What is the key difference between FOXO4-DRI and Thymalin?
FOXO4-DRI is a senolytic peptide targeting p53 displacement; thymalin is a thymic polypeptide targeting immune reconstitution - completely different aging mechanisms (cellular clearance vs. immune restoration).
Evidence Comparison
FOXO4-DRI: Baar 2017 (Cell) in aged mice, single group, no human data. Thymalin: Khavinson group human studies in elderly subjects showing immune marker improvements, but all from a single Russian group with no independent replication. Both have single-group evidence; thymalin has more human exposure data.
Evidence Context Favoring FOXO4-DRI
Senescence-focused aging research using the Baar 2017 paradigm.
Evidence Context Favoring Thymalin
Immune aging (immunosenescence) research where thymic restoration is the target, accepting Khavinson-group data limitations.
Side-by-Side Snapshot
| Evidence grade | FOXO4-DRI: Level D Thymalin: Level C |
|---|---|
| Research status | FOXO4-DRI: Preclinical Thymalin: Approved Outside US |
| Primary category | FOXO4-DRI: Anti-Aging & Longevity Thymalin: Anti-Aging & Longevity |
| Cited studies | FOXO4-DRI: 2 Thymalin: 3 |